Talk:Guduchi: Difference between revisions
No edit summary |
|||
| (4 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
Guduchi (Tinospora cordifolia (WILLD.) HOOK.F. & THOMS.) | Guduchi (Tinospora cordifolia (WILLD.) HOOK.F. & THOMS.) | ||
''Guduchi'' ( | ''Guduchi'' (गुडूची), commonly known as ' Giloy', is the Sanskrit name for the medicinal plant Tinospora cordifolia (Willd.) Hook. f. & Thomson of the family [[Menispermaceae]].<ref name="AYUSHDossier">{{Cite web |url=https://ayush.gov.in/resources/pdf/quality_standards/guduchi_Book-Dossier.pdf |title=Technical Dossier on - Guduchi |format=PDF |publisher=Ministry of AYUSH, Government of India |year=2019 |access-date=2026-04-13}}</ref> It holds a prominent place in [[Ayurveda]] as a [[Rasayana]] (rejuvenative) herb and is widely used for conditions such as fever, jaundice, musculoskeletal disorders, skin diseases, and metabolic ailments.<ref name="AYUSHDossier"/> | ||
| Line 15: | Line 15: | ||
|data4 = Available | |data4 = Available | ||
|label5 = Contributors | |label5 = Contributors | ||
|data5 = | |data5 = Deole Y.S. | ||
|label6 = Year of publication | |label6 = Year of publication | ||
|data6 = 2026 | |data6 = 2026 | ||
| Line 478: | Line 478: | ||
== Safety and hepatotoxicity == | == Safety and hepatotoxicity == | ||
In recent years, several case reports and reviews have described herb‑induced liver injury associated with Guduchi or ''Tinospora''‑containing products.<ref name="LiverTox"/ | In recent years, several case reports and reviews have described herb‑induced liver injury associated with Guduchi or ''Tinospora''‑containing products.<ref name="LiverTox"/>,<ref name="PMC2021LiverInjury">Björnsson ES, Navarro VJ, Chalasani N. Liver Injury Following Tinospora Cordifolia Consumption: Drug-Induced AIH, or de novo AIH? J Clin Exp Hepatol. 2022 Jan-Feb;12(1):6-9. doi: 10.1016/j.jceh.2021.11.014. Epub 2021 Nov 29. PMID: 35068778; PMCID: PMC8766689.</ref> | ||
The NIH LiverTox resource notes that Guduchi‑associated liver injury can range from mild elevation of liver enzymes to clinically significant hepatitis and, rarely, acute liver failure, with some cases showing autoimmune‑like features.<ref name="LiverTox"/> Many cases occur in patients with pre‑existing liver disease or autoimmune predisposition and may be idiosyncratic or immune‑mediated.<ref name="LiverTox | The NIH LiverTox resource notes that Guduchi‑associated liver injury can range from mild elevation of liver enzymes to clinically significant hepatitis and, rarely, acute liver failure, with some cases showing autoimmune‑like features.<ref name="LiverTox"/> Many cases occur in patients with pre‑existing liver disease or autoimmune predisposition and may be idiosyncratic or immune‑mediated.<ref name="LiverTox"/> | ||
The AYUSH technical dossier highlights that many published liver injury reports lack detailed baseline documentation and may mix different species and preparations, underscoring the need for careful botanical identification, product quality control, and medical supervision, especially in patients with pre‑existing liver conditions.<ref name="AYUSHDossier"/> | The AYUSH technical dossier highlights that many published liver injury reports lack detailed baseline documentation and may mix different species and preparations, underscoring the need for careful botanical identification, product quality control, and medical supervision, especially in patients with pre‑existing liver conditions.<ref name="AYUSHDossier"/> | ||
| Line 486: | Line 486: | ||
== Current research trends == | == Current research trends == | ||
PubMed‑based trend analyses indicate a substantial increase in publications on Guduchi, rising from several hundred articles in the early 2010s to over 900 indexed studies by 2024, reflecting growing scientific interest. | PubMed‑based trend analyses indicate a substantial increase in publications on Guduchi, rising from several hundred articles in the early 2010s to over 900 indexed studies by 2024, reflecting growing scientific interest.<ref name="AYUSHDossier"/> This growth reflects heightened scientific and public interest but does not, by itself, equate to high‑quality clinical evidence.<ref name="MetabolicReview2025"/> | ||
Most of the current evidence is from preclinical studies, mechanistic investigations, small trials, and narrative reviews; large, well‑designed randomized controlled trials are still limited.<ref name="MetabolicReview2025 | Most of the current evidence is from preclinical studies, mechanistic investigations, small trials, and narrative reviews; large, well‑designed randomized controlled trials are still limited.<ref name="MetabolicReview2025"/> | ||
== Clinical position == | == Clinical position == | ||
From an Ayurvedic perspective, Guduchi is regarded as a classical Rasayana with broad therapeutic indications, supported by long‑standing clinical experience.<ref name="AYUSHDossier"/><ref name="OnePlantManyRoles"/> From a modern evidence‑based medicine standpoint, it is best viewed as a promising but not yet fully established botanical agent for conditions such as metabolic syndrome, certain inflammatory disorders, and liver and immune‑mediated conditions.<ref name="MetabolicReview2025 | From an Ayurvedic perspective, Guduchi is regarded as a classical Rasayana with broad therapeutic indications, supported by long‑standing clinical experience.<ref name="AYUSHDossier"/><ref name="OnePlantManyRoles"/> From a modern evidence‑based medicine standpoint, it is best viewed as a promising but not yet fully established botanical agent for conditions such as metabolic syndrome, certain inflammatory disorders, and liver and immune‑mediated conditions.<ref name="MetabolicReview2025"/> | ||
Use in clinical practice should emphasize:<ref name="LiverTox"/><ref name="AYUSHDossier"/> | Use in clinical practice should emphasize:<ref name="LiverTox"/><ref name="AYUSHDossier"/> | ||